Neurones S.A.

ENXTPA:NRO Stock Report

Market Cap: €960.8m

Neurones Future Growth

Future criteria checks 1/6

Neurones is forecast to grow earnings and revenue by 10.9% and 5.3% per annum respectively. EPS is expected to grow by 10.9% per annum. Return on equity is forecast to be 14.6% in 3 years.

Key information

10.9%

Earnings growth rate

10.85%

EPS growth rate

IT earnings growth10.3%
Revenue growth rate5.3%
Future return on equity14.62%
Analyst coverage

Low

Last updated07 Aug 2025

Recent future growth updates

Recent updates

Neurones (EPA:NRO) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Oct 02
Neurones (EPA:NRO) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Returns At Neurones (EPA:NRO) Appear To Be Weighed Down

Aug 30
Returns At Neurones (EPA:NRO) Appear To Be Weighed Down

Neurones (EPA:NRO) Has A Rock Solid Balance Sheet

Jun 24
Neurones (EPA:NRO) Has A Rock Solid Balance Sheet

Neurones S.A.'s (EPA:NRO) CEO Looks Due For A Compensation Raise

May 30
Neurones S.A.'s (EPA:NRO) CEO Looks Due For A Compensation Raise

Neurones S.A.'s (EPA:NRO) Shares May Have Run Too Fast Too Soon

Apr 04
Neurones S.A.'s (EPA:NRO) Shares May Have Run Too Fast Too Soon

What Neurones S.A.'s (EPA:NRO) P/E Is Not Telling You

Jul 27
What Neurones S.A.'s (EPA:NRO) P/E Is Not Telling You

Returns On Capital At Neurones (EPA:NRO) Have Hit The Brakes

Apr 26
Returns On Capital At Neurones (EPA:NRO) Have Hit The Brakes

Slowing Rates Of Return At Neurones (EPA:NRO) Leave Little Room For Excitement

Dec 01
Slowing Rates Of Return At Neurones (EPA:NRO) Leave Little Room For Excitement

If EPS Growth Is Important To You, Neurones (EPA:NRO) Presents An Opportunity

May 18
If EPS Growth Is Important To You, Neurones (EPA:NRO) Presents An Opportunity

Neurones' (EPA:NRO) Returns Have Hit A Wall

Feb 10
Neurones' (EPA:NRO) Returns Have Hit A Wall

Slowing Rates Of Return At Neurones (EPA:NRO) Leave Little Room For Excitement

Oct 26
Slowing Rates Of Return At Neurones (EPA:NRO) Leave Little Room For Excitement

Does Neurones (EPA:NRO) Deserve A Spot On Your Watchlist?

Sep 22
Does Neurones (EPA:NRO) Deserve A Spot On Your Watchlist?

Neurones (EPA:NRO) Will Pay A Smaller Dividend Than Last Year

Apr 28
Neurones (EPA:NRO) Will Pay A Smaller Dividend Than Last Year

Should You Be Adding Neurones (EPA:NRO) To Your Watchlist Today?

Jan 25
Should You Be Adding Neurones (EPA:NRO) To Your Watchlist Today?

Returns At Neurones (EPA:NRO) Appear To Be Weighed Down

Jan 06
Returns At Neurones (EPA:NRO) Appear To Be Weighed Down

Returns On Capital At Neurones (EPA:NRO) Paint A Concerning Picture

Jul 20
Returns On Capital At Neurones (EPA:NRO) Paint A Concerning Picture

Is Neurones S.A. (EPA:NRO) Trading At A 25% Discount?

May 06
Is Neurones S.A. (EPA:NRO) Trading At A 25% Discount?

Some Investors May Be Worried About Neurones' (EPA:NRO) Returns On Capital

Mar 24
Some Investors May Be Worried About Neurones' (EPA:NRO) Returns On Capital

Neurones S.A.'s (EPA:NRO) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Mar 09
Neurones S.A.'s (EPA:NRO) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

The Neurones (EPA:NRO) Share Price Has Gained 54% And Shareholders Are Hoping For More

Feb 16
The Neurones (EPA:NRO) Share Price Has Gained 54% And Shareholders Are Hoping For More

Here's Why Neurones's (EPA:NRO) Statutory Earnings Are Arguably Too Conservative

Jan 25
Here's Why Neurones's (EPA:NRO) Statutory Earnings Are Arguably Too Conservative

What Percentage Of Neurones S.A. (EPA:NRO) Shares Do Insiders Own?

Jan 11
What Percentage Of Neurones S.A. (EPA:NRO) Shares Do Insiders Own?

Should Neurones S.A. (EPA:NRO) Be Part Of Your Dividend Portfolio?

Dec 28
Should Neurones S.A. (EPA:NRO) Be Part Of Your Dividend Portfolio?

Are Neurones S.A. (EPA:NRO) Investors Paying Above The Intrinsic Value?

Dec 15
Are Neurones S.A. (EPA:NRO) Investors Paying Above The Intrinsic Value?

What We Learned About Neurones' (EPA:NRO) CEO Pay

Dec 02
What We Learned About Neurones' (EPA:NRO) CEO Pay

Investors Who Bought Neurones (EPA:NRO) Shares Five Years Ago Are Now Up 39%

Nov 17
Investors Who Bought Neurones (EPA:NRO) Shares Five Years Ago Are Now Up 39%

Neurones (EPA:NRO) Is Growing Earnings But Are They A Good Guide?

Jun 30
Neurones (EPA:NRO) Is Growing Earnings But Are They A Good Guide?

Earnings and Revenue Growth Forecasts

ENXTPA:NRO - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202795266N/AN/A1
12/31/202689857N/AN/A1
12/31/202585148N/AN/A1
6/30/2025832516678N/A
3/31/2025821526981N/A
12/31/2024810537284N/A
9/30/2024793515873N/A
6/30/2024775484362N/A
3/31/2024758494967N/A
12/31/2023741495472N/A
9/30/2023724495974N/A
6/30/2023707486476N/A
3/31/2023686465465N/A
12/31/2022665444455N/A
9/30/2022642434251N/A
6/30/2022618414047N/A
3/31/2022599404956N/A
12/31/2021580385864N/A
9/30/2021570375865N/A
6/30/2021559365866N/A
3/31/2021542335967N/A
12/31/2020524316067N/A
9/30/2020518306169N/A
6/30/2020511286370N/A
3/31/2020510305866N/A
12/31/2019510315361N/A
9/30/2019505304653N/A
6/30/2019501303845N/A
3/31/201949528N/A38N/A
12/31/201849026N/A31N/A
9/30/201848726N/A28N/A
6/30/201848326N/A25N/A
3/31/201848427N/A24N/A
12/31/201748527N/A23N/A
9/30/201747827N/A24N/A
6/30/201747027N/A25N/A
3/31/201745926N/A23N/A
12/31/201644725N/A21N/A
9/30/201643624N/A21N/A
6/30/201642523N/A20N/A
3/31/201641222N/A25N/A
12/31/201539921N/A30N/A
9/30/201538621N/A30N/A
6/30/201537421N/A29N/A
3/31/201536421N/A29N/A
12/31/201435521N/A29N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NRO's forecast earnings growth (10.9% per year) is above the savings rate (1.9%).

Earnings vs Market: NRO's earnings (10.9% per year) are forecast to grow slower than the French market (12.3% per year).

High Growth Earnings: NRO's earnings are forecast to grow, but not significantly.

Revenue vs Market: NRO's revenue (5.3% per year) is forecast to grow slower than the French market (5.5% per year).

High Growth Revenue: NRO's revenue (5.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: NRO's Return on Equity is forecast to be low in 3 years time (14.6%).


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/03 16:51
End of Day Share Price 2025/10/03 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Neurones S.A. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gilbert FerrandArkeon Finance
Alexandre PlaudCIC Market Solutions (ESN)
Richard-Maxime BeaudouxNatixis S.A.